Laurus Labs Limited (BSE: 540222, NSE: Lauruslabs, ISIN: INE947Q01010), a leading research and development driven pharmaceutical company has completed the US Food and Drug Administration (USFDA) inspection of its API facilities in Units 1 & 3 at Parawada, Visakhapatnam, Andhra Pradesh, with two observations which are procedural in nature.
This is a regular surveillance audit by USFDA, and no data integrity issues were observed in the inspection.
Shares of Laurus Labs Ltd was last trading in BSE at Rs.341.45 as compared to the previous close of Rs. 335.95. The total number of shares traded during the day was 4244 in over 163 trades.
The stock hit an intraday high of Rs. 341.45 and intraday low of 332.65. The net turnover during the day was Rs. 1430645.